Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Common Equity (2016 - 2025)

Syndax Pharmaceuticals has reported Common Equity over the past 11 years, most recently at $64.6 million for Q4 2025.

  • Quarterly results put Common Equity at $64.6 million for Q4 2025, down 77.57% from a year ago — trailing twelve months through Dec 2025 was $64.6 million (down 77.57% YoY), and the annual figure for FY2025 was $64.6 million, down 77.57%.
  • Common Equity for Q4 2025 was $64.6 million at Syndax Pharmaceuticals, down from $115.4 million in the prior quarter.
  • Over the last five years, Common Equity for SNDX hit a ceiling of $554.2 million in Q4 2023 and a floor of $64.6 million in Q4 2025.
  • Median Common Equity over the past 5 years was $360.6 million (2022), compared with a mean of $323.7 million.
  • Biggest five-year swings in Common Equity: soared 326.48% in 2021 and later crashed 77.57% in 2025.
  • Syndax Pharmaceuticals' Common Equity stood at $408.4 million in 2021, then grew by 14.47% to $467.4 million in 2022, then increased by 18.56% to $554.2 million in 2023, then plummeted by 48.01% to $288.1 million in 2024, then crashed by 77.57% to $64.6 million in 2025.
  • The last three reported values for Common Equity were $64.6 million (Q4 2025), $115.4 million (Q3 2025), and $157.4 million (Q2 2025) per Business Quant data.